Eledon Q1 net loss $6.5M; cash $124.9M; on track for BESTOW topline in Q4

Eledon Pharmaceuticals, Inc.

2025-Q1 EPS reported -$0.08

Net loss of $6.5M ($0.08/share) vs $23.6M loss in Q1 2024; adjusted net loss $16.6M vs $10.3M.
Cash, equivalents and short-term investments $124.9M as of March 31, 2025; funds operations to end of 2026.
R&D expenses $13.5M (incl. $1.0M SBC) vs $7.4M prior year; G&A $4.4M vs $3.5M.
Tegoprubart used in second genetically modified pig kidney transplant at Mass General; patient discharged without dialysis.
Topline Phase 2 BESTOW results on track for Q4 2025; interim Phase 1b data expected August 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.